my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
02-11-2009: Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). Affimed will receive a funded grant totaling more than €550.000 to carry out its part of the project.
BMBF supports the Molecular Imaging Technology Initiative for the development of new diagnostic methods and imaging technologies for clinical use and pharmaceutical applications.
Within this collaboration, Affimed will identify and isolate new molecules binding to membrane-associated targets on tumour tissues, using its highly diverse human antibody libraries. The optimised binding molecules in their final format will be further characterized in vitro by the other above mentioned collaboration partners. The main goal is to find new diagnostic tracer molecules for use in imaging technologies, but identified molecules could also be used for in vitro diagnostic purposes or the development of new pharmaceutical therapeutics.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
Affimed enrolls first patients in Phase I Hodgkin's Lymphoma Study
Affimed Therapeutics AG announced that the first patients with Hodgkin's Lymphoma have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. The Phase I repeat dose escalation study will enroll approximately 40 Hodgkin's Lymphoma patients across two centers in Europe and ... more
Affimed Therapeutics AG expands clinical development team
In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at A ... more
Affimed joins the Molecular Imaging Technology Initiative
Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). A ... more
Affimed is a private biopharmaceutical company specializing in the development of recombinant antibodies. more
The Lead Discovery Center GmbH (LDC), based in Dortmund, Germany, a spin-off from Max-Planck-Innovation GmbH (MI) in Munich, with expertise in small molecule pharmaceutical drug discovery, has successfully licensed its first lead structure to a pharma partner. The agreement grants Bayer Sch ... more
EU regulators okay Qlaira for the treatment of heavy menstrual bleeding
Bayer Schering Pharma AG, Germany, has successfully concluded the European registration procedure for the introduction of Qlaira in the new indication treatment of heavy menstrual bleeding in women without organic pathology who desire oral contraception. The Netherlands served as Reference ... more
Bayer launches Betaferon in China
Bayer Schering Pharma announced the upcoming launch in China of Betaferon® (interferon beta-1b) for the treatment of relapsing-remitting forms of multiple sclerosis (MS). Betaferon is already approved in over 100 countries worldwide. With Betaferon and Gadovist®1.0, which was also recently ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Our products and services are designed to benefit people and improve their quality of life. At the same time we want to create value through innovation, growth and high earni ... more
Bayer Schering Pharma’s goal is a leading market position in each of its specialist fields. With its distinctive expertise, the company engages in research on new drugs which, as innovative therapies, make an essential contribution toward improving people’s quality of life. Our outstanding ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
